Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 5/20 | 0.64 |
| ▸ | BCR | P11274 | 4/20 | 0.64 |
| ▸ | PRKCA | P17252 | 4/20 | 0.64 |
| ▸ | CDK2 | P24941 | 7/20 | 0.62 |
| ▸ | CDK4 | P11802 | 6/20 | 0.62 |
| ▸ | EGFR | P00533 | 2/20 | 0.60 |
| ▸ | SRC | P12931 | 2/20 | 0.60 |
| ▸ | PRKACA | P17612 | 1/20 | 0.59 |
| ▸ | PRKACG | P22612 | 1/20 | 0.59 |
| ▸ | PRKACB | P22694 | 1/20 | 0.59 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.59 |
| ▸ | GSK3B | P49841 | 2/20 | 0.57 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.57 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.57 |
| ▸ | PLK1 | P53350 | 1/20 | 0.56 |
| ▸ | FLT3 | P36888 | 1/20 | 0.55 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.55 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.55 |
| ▸ | CDK1 | P06493 | 4/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL144954 | 0.82 | CCNB2 (0.76) | ABL1BCRPRKCACDK2EGFR | |
| SCHEMBL31588329 | 0.82 | CCNB2 (0.76) | ABL1BCRPRKCACDK2EGFR | |
| SCHEMBL13608591 | 0.82 | EGFR (0.62) | ABL1BCRPRKCACDK2EGFR | |
| SCHEMBL29129146 | 0.81 | EGFR (0.65) | CDK2EGFRPTK6CDK1CCNB1 | |
| SCHEMBL17831508 | 0.81 | FLT3 (0.65) | ABL1BCRPRKCACDK2CDK4 | |
| SCHEMBL824007 | 0.80 | ABL1 (0.84) | ABL1BCRPRKCACDK2CDK4 | |
| SCHEMBL1886 | 0.78 | ABL1 (1.00) | ABL1BCRPRKCACDK2CDK4 | |
| SCHEMBL140969 | 0.77 | CCNB2 (0.64) | ABL1BCRPRKCACDK2CDK4 | |
| SCHEMBL5206934 | 0.76 | CDK2 (1.00) | ABL1BCRPRKCACDK2CDK4 | |
| SCHEMBL1144 | 0.76 | ABL1 (1.00) | ABL1BCRPRKCACDK2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | claimed |
| CN-101111490-A | 4- (1H-indol-3-yl) -pyrimidin-2-ylamine derivatives and their therapeutic use | CYCLACEL LTD (GB) | 2008-01-23 | — | — | CN | claimed |
| EP-1836194-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | Cyclacel Limited (GB) | 2007-09-26 | — | — | EP | claimed |
| WO-2006075152-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | CYCLACEL LIMITED (GB) | 2006-07-20 | — | — | WO | claimed |
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| CN-101111490-A | 4- (1H-indol-3-yl) -pyrimidin-2-ylamine derivatives and their therapeutic use | CYCLACEL LTD (GB) | 2008-01-23 | — | — | CN | disclosed |
| EP-1836194-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | Cyclacel Limited (GB) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006075152-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | CYCLACEL LIMITED (GB) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | ABL1, CDK2, JAK2 | ABL1 1/4885BCR 1680/4885PRKCA 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.